Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Jul 4:5:70.
doi: 10.1186/1471-2407-5-70.

Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases

Andrea Veronesi  1 , Clelia de Giacomi, Maria D Magri, Davide Lombardi, Martina Zanetti, Cristina Scuderi, Riccardo Dolcetti, Alessandra Viel, Diana Crivellari, Ettore Bidoli, Mauro Boiocchi
Affiliations

Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases

Andrea Veronesi et al. BMC Cancer. .

Abstract

Background: The clinical and pathological characteristics and the clinical course of patients with breast cancer and BRCA 1-2 mutation are poorly known.

Methods: From 1997, patients with breast cancer and a family history of breast or ovarian cancer were offered BRCA testing. The clinical and pathological features of patients with known BRCA status were retrospectively assessed and comparisons were made between cancers arising in BRCA positive and BRCA wild type (WT) patients respectively. Type of treatment, pattern of relapse, event (local relapse, contralateral breast cancer, metastases) free and overall survival were also compared in the two groups. Out of the 210 patients tested, 125 had been treated and followed-up at our Institution and were evaluated in this study.

Results: BRCA positive patients tended to be more often premenopausal (79% vs 65%) and to have positive lymphnodes (63% vs 49%), poorly differentiated tumours (76% vs 40%--p = 0.002 at univariate analysis, not significant at multivariate analysis) and negative estrogen receptors (43% vs 29%). Treatment was not different in the two groups. In the 86 BRCA-WT patients, the first event was a local relapse in 3 (3%), metachronous contralateral breast cancer in 7 (8%) and distant metastases in 16 (19%). In the 39 BRCA positive patients, the corresponding figures were 3 (8%), 8 (21%) and 3 (8%). There was no difference in event free survival, with a median of 180 months in both groups of patients. At 20 years, projected survival was 85% for BRCA positive patients and 55% for BRCA-WT, but this difference was not statistically significant.

Conclusion: Although BRCA positive patients have more frequently negative prognostic factors, their prognosis appears to be equal to or better than in patients with BRCA-WT.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Event free survival.
Figure 2
Figure 2
Overall survival.
See this image and copyright information in PMC

References

    1. Blackwood MA, Weber BL. BRCA1 and BRCA2: from molecular genetics to clinical medicine. J Clin Oncol. 1998;16:1969–1977. - PubMed
    1. Chappuis PO, Nethercot V, Foulkes WD. Clinico-pathological characteristics of BRCA-1 and BRCA-2 related breast cancer. Semin Surg Oncol. 2000;18:287–295. doi: 10.1002/(SICI)1098-2388(200006)18:4<287::AID-SSU3>3.0.CO;2-5. - DOI - PubMed
    1. Albano W, Recabaren J, Lynch H. Natural history of hereditary cancer of the breast and colon. Cancer. 1982;50:360–363. - PubMed
    1. Andersson D, Badzioch M. Survival in familial breast cancer patients. Cancer. 1986;58:360–365. - PubMed
    1. Chang J, Elledge RM. Clinical management of women with genomic BRCA1 and BRCA2 mutations. Breast Cancer Res Treat. 2001;69:101–113. doi: 10.1023/A:1012203917104. - DOI - PubMed